NCT03100071

Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients

A Pilot Study in Cancer Patients With Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in the Upper Extremity Treated With Low Molecular Weight Heparin (LMWH) and Apixaban (Catheter 3)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 70 (estimated)
• Sponsor: Michael Kovacs · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.

Detailed description

Cancer patients who have developed blood clot in the arm that has the central venous catheter will be treated with standard of care blood thinning injection of low molecular weight heparin for 1 week and then for apixaban 5 mg twice daily for the rest of 11 weeks. Data will be collected to see if the central venous catheter "survived" or remained in place and did not have to be taken out because of the clot.

Conditions

• Cancer Patients
• Central Venous Catheter Thrombosis
• Upper Extremity Thrombosis

Interventions

Type	Name	Description
DRUG	Apixaban	Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.

Timeline

• Start date: 2017-05-15
• Primary completion: 2021-08-01
• Completion: 2021-08-01
• First posted: 2017-04-04
• Last updated: 2021-08-03

Locations

2 sites across 1 country: Canada

Regulatory

• FDA-regulated drug study